Emmessar Biotech & Nutrition Limited (BOM:524768)
India · Delayed Price · Currency is INR 24.36
+0.46 (1.92%)
At close: Aug 18, 2026
BOM:524768 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 3.37 | 3.71 | 6.11 | 5.55 | 10.19 | 3.65 |
Other Revenue | 20.41 | 20.36 | 15.24 | 14.86 | 14.96 | 14.08 |
| 23.78 | 24.07 | 21.35 | 20.42 | 25.15 | 17.73 | |
Revenue Growth | -12.25% | 12.75% | 4.55% | -18.82% | 41.83% | -79.03% |
Cost of Revenue | 0.75 | 0.88 | 1.85 | 2 | 4.34 | 1.35 |
Gross Profit | 23.03 | 23.19 | 19.49 | 18.42 | 20.81 | 16.38 |
Selling, General & Admin | 11.37 | 10.79 | 9.75 | 10.06 | 8.71 | 8.02 |
Other Operating Expenses | 5.54 | 5.58 | 4.03 | 4.15 | 3.86 | 2.57 |
Operating Expenses | 17.89 | 17.37 | 14.76 | 15.18 | 13.5 | 11.52 |
Operating Income | 5.14 | 5.82 | 4.74 | 3.24 | 7.31 | 4.86 |
Interest Expense | -0.03 | -0.03 | -0.01 | - | - | - |
Interest & Investment Income | - | - | 4.83 | 4.9 | 2.41 | 2.09 |
Currency Exchange Gain (Loss) | - | - | 0.01 | -0.02 | -0.05 | -0.09 |
Other Non Operating Income (Expenses) | - | - | - | -0 | - | - |
EBT Excluding Unusual Items | 5.11 | 5.8 | 9.58 | 8.12 | 9.67 | 6.87 |
Gain (Loss) on Sale of Investments | - | - | 0.01 | 0.01 | 0 | - |
Pretax Income | 5.11 | 5.8 | 9.58 | 8.13 | 9.67 | 9.32 |
Income Tax Expense | 1.15 | 1.44 | 6.42 | 0.63 | 4.63 | 4.56 |
Net Income | 3.96 | 4.36 | 3.16 | 7.5 | 5.04 | 4.75 |
Net Income to Common | 3.96 | 4.36 | 3.16 | 7.5 | 5.04 | 4.75 |
Net Income Growth | -0.53% | 37.86% | -57.82% | 48.79% | 5.97% | -67.21% |
Shares Outstanding (Basic) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Outstanding (Diluted) | 5 | 5 | 5 | 5 | 5 | 5 |
Shares Change | 3.50% | 7.72% | - | - | - | -0.00% |
EPS (Basic) | 0.74 | 0.81 | 0.63 | 1.50 | 1.01 | 0.95 |
EPS (Diluted) | 0.74 | 0.81 | 0.61 | 1.48 | 1.01 | 0.95 |
EPS Growth | -3.90% | 32.79% | -58.78% | 46.77% | 5.97% | -67.21% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 2.57 | 2.24 | 6.45 | 3.5 | 19.64 |
Free Cash Flow Per Share | - | 0.48 | 0.45 | 1.29 | 0.70 | 3.93 |
Gross Margin | 96.84% | 96.35% | 91.32% | 90.21% | 82.75% | 92.38% |
Operating Margin | 21.61% | 24.19% | 22.19% | 15.87% | 29.07% | 27.43% |
Profit Margin | 16.66% | 18.11% | 14.81% | 36.72% | 20.03% | 26.81% |
Free Cash Flow Margin | - | 10.66% | 10.48% | 31.57% | 13.91% | 110.78% |
EBITDA | 6.15 | 6.82 | 5.71 | 4.22 | 8.25 | 5.79 |
EBITDA Margin | 25.85% | 28.35% | 26.77% | 20.64% | 32.79% | 32.64% |
D&A For EBITDA | 1.01 | 1 | 0.98 | 0.98 | 0.94 | 0.92 |
EBIT | 5.14 | 5.82 | 4.74 | 3.24 | 7.31 | 4.86 |
EBIT Margin | 21.61% | 24.19% | 22.19% | 15.87% | 29.07% | 27.43% |
Effective Tax Rate | 22.51% | 24.79% | 67.00% | 7.75% | 47.89% | 48.96% |
Revenue as Reported | 23.78 | 24.07 | 26.2 | 25.47 | 27.7 | 22.84 |
Advertising Expenses | - | - | 0.23 | 0.22 | 0.17 | 0.17 |